According to TipRanks.com, Meacham is a 5-star analyst with an average return of 15.1% and a 60.5% success rate. Meacham covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Merrimack Pharmaceuticals.

Currently, the analyst consensus on Vertex Pharm. is Moderate Buy and the average price target is $101.75, representing a 17.1% upside.

In a report issued on November 18, Janney Montgomery also initiated coverage with a Hold rating on the stock with a $98 price target.Nivalis Therapeutics (NASDAQ: NVLS)

According to TipRanks.com, Nadeau is a 3-star analyst with an average return of 1.8% and a 47.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

According to TipRanks.com, Eckard is a 1-star analyst with an average return of -4.6% and a 34.8% success rate. Eckard covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Mirati Therapeutics, and Juno Therapeutics.

Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $53.